Case: Patents/Anticipation (D. Del.)

Galderma Laboratories LP’s patents for Soolantra (ivermectin), a rosacea treatment, are invalid as anticipated by a prior patent. The prior patent involves a method for the treatment of rosacea — a chronic inflammatory disorder — by using a once daily dose of 1 percent ivermectin orally administered or topically applied. And Galderma’s claimed treatment method involves the once daily topical administration to skin affected by rosacea lesions of a pharmaceutical composition comprising 1 percent by weight ivermectin and a pharmaceutically acceptable carrier. The prior patent also anticipates Soolantra’s claimed efficacies of a significant reduction in inflammatory lesion count and a ...